Miranda Adrian 4

What Happened

• Miranda Adrian, Chief Medical Officer and SVP, Science & Technology at Neuraxis, received a grant of 47,569 restricted stock units (RSUs) on January 22, 2026. The filing reports a per-share grant value of $4.63, for a total grant value of $220,244. This was an award/compensation grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-22 (reported on Form 4 filed 2026-03-02)
• Grant details: 47,569 RSUs at $4.63 per share; total reported value $220,244
• Shares owned after transaction: not specified in the Form 4 filing
• Footnote: RSUs were granted under Neuraxis, Inc.’s 2022 Omnibus Securities and Incentive Plan and vest in three equal annual installments over three years
• Timeliness: The Form 4 was filed on 2026-03-02 for a 2026-01-22 grant; this appears to be later than the typical 2-business-day Form 4 reporting window

Context

• RSUs are a compensation award (a derivative grant). They convert to actual shares only as they vest per the stated schedule, so this does not represent an immediate market purchase or sale. Such grants are common for executive compensation and should be viewed as compensation rather than a direct bullish or bearish trading signal.